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ORIGINAL ARTICLE
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ABSTRACT
Background: Biliary tract cancer (BTC) is an uncommon cancer with an unfavorable prognosis. Since
2010, the standard of care for patients with unresectable BTC is palliative treatment with gemcitabine
plus cisplatin, based on the landmark phase III ABC-02 trial. This current study aims to evaluate the effi-
cacy and safety of gemcitabine and cisplatin in patients with unresectable cholangiocarcinoma and
gallbladder cancer in daily practice that meet the criteria for the ABC-02 trial in comparison to patients
who did not.
Methods: Patients diagnosed with unresectable BTC between 2010 and 2015 with an indication for
gemcitabine and cisplatin were included. We divided these patients into three groups: (I) patients who
received chemotherapy and met the criteria of the ABC-02 trial, (II) patients who received chemother-
apy and did not meet these criteria and (III) patients who had an indication for chemotherapy, but
received best supportive care without chemotherapy. Primary outcome was overall survival (OS) and
secondary outcome was progression-free survival (PFS).
Results: We collected data of 208 patients, of which 138 (66.3%) patients received first line chemother-
apy with gemcitabine and cisplatin. Median OS of 69 patients in group I, 63 patients in group II and
65 patients in group III was 9.6 months (95%CI¼ 6.7–12.5), 9.5 months (95%CI¼ 7.7–11.3) and 7.6
months (95%CI¼ 5.0–10.2), respectively. Median PFS was 6.0 months (95%CI¼ 4.4–7.6) in group I and
5.1 months (95%CI¼ 3.7–6.5) in group II. Toxicity and number of dose reductions (p¼ .974) were com-
parable between the two chemotherapy groups.
Conclusion: First-line gemcitabine and cisplatin is an effective and safe treatment for patients with
unresectable BTC who do not meet the eligibility criteria for the ABC-02 trial. Median OS, PFS and
treatment side effects were comparable between the patients who received chemotherapy (group I vs.
group II).
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Introduction
Biliary tract cancer (BTC) is an uncommon cancer in developed
countries consisting of cholangiocarcinoma and gall bladder
cancer. The incidence of gall bladder cancer and extrahepatic
cholangiocarcinoma in the European Union is 3.2 and 5.4/
100,000 per year for males and females, respectively [1]. There
are approximately 600 new cases of BTC in the Netherlands per
year, and the incidence is rising [2]. Surgical resection is the
only curative treatment for patients with BTC but most patients
have (locally) advanced disease or metastasis at presentation
and are not eligible for surgical resection [3,4].
Patients with unresectable BTC are currently treated with
a combination of gemcitabine and cisplatin, based on the
phase III ABC-02 trial. This trial demonstrated a significant
survival advantage of this combination without the addition
of substantial toxicity compared to gemcitabine monother-
apy [5]. The promising results of this clinical trial led to incor-
porating this treatment regimen, consisting of 1000mg/m2
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gemcitabine and 25mg/m2 cisplatin in a three-weekly cycle
with administrations on day one and eight, in national and
international guidelines, including the European Society for
Medical Oncology (ESMO) guideline [6].
Although this combination of gemcitabine plus cisplatin
showed survival advantage when compared with gemcita-
bine alone, this regimen was studied in a group of patients
complying with the inclusion criteria of the ABC-02 trial.
However, most patients in clinical practice do not fulfill these
criteria and the efficacy and toxicity of this regimen has not
been evaluated in these patients. Furthermore, the effect of
gemcitabine plus cisplatin in patients with unresectable BTC
has not been compared with patients receiving best support-
ive care.
No difference in median overall survival (OS) between trial
and non-trial patients was observed in similar retrospective
studies in colorectal and breast cancer [7,8]. In a study per-
formed in men with metastatic castration resistant prostate
cancer, it has been demonstrated that treatment in daily
practice is associated with a shorter survival and more tox-
icity compared with men treated in a clinical trial [9].
Because of the poor prognosis of patients with BTC and
the possible adverse effects of chemotherapy, it is important
to know if this ABC-02 chemotherapy treatment regimen
could also be used in patients who do not fulfill the original
inclusion criteria [5]. Therefore the aim of this study was to
evaluate the efficacy and safety of gemcitabine and cisplatin
in daily practice in unresectable BTC patients, who do not
meet the eligibility criteria for the ABC-02 trial, compared
with those who meet the inclusion criteria for this trial.
To be able to answer this question, it is necessary to study a
subsequent population of patients that is treated in daily prac-
tice with a combination of gemcitabine and cisplatin. In add-
ition, we aimed to compare patients who received
chemotherapy and patients who received best supportive care.
Methods
Study population and data acquisition
All patients with unresectable BTC between January 2010
and January 2015 in the Academic Medical Center (AMC),
Amsterdam, the Netherlands and Erasmus MC University
Medical Center (EMC), Rotterdam, the Netherlands, were
identified. Referring hospitals were contacted for additional
data on the referred BTC patients. BTC was defined as intra-
or extrahepatic cholangiocarcinoma or gallbladder cancer. If
no histopathological evidence was obtained, the diagnosis
was established by the multidisciplinary hepatopancreatobili-
ary team based on clinical, radiological, endoscopic, labora-
tory findings and follow-up. Patients were deemed
unresectable when distant metastases were present or when
radical resection was not possible due to locally advanced
disease. Also recurrent disease after surgery was considered
as unresectable. Patients were excluded if they received first-
line chemotherapy other than gemcitabine and cisplatin.
Patient characteristics (e.g., age, sex), clinical parameters (e.g.,
cholangitis), laboratory results (e.g., white-cell count, platelet
count), chemotherapy treatment details (e.g., dose, number
of cycles, toxicity) and previous interventions (surgery, percu-
taneous transhepatic drainage (PTC), endoscopic retrograde
cholangiopancreatography (ERCP), radiotherapy) were col-
lected from medical records.
The study population was divided into three groups: (I)
patients who received chemotherapy and met the criteria of
the ABC-02 trial, (II) patients who received chemotherapy and
did not meet these criteria and (III) patients who were eli-
gible for chemotherapy but received best supportive care
without any chemotherapy. The criteria used in the ABC-02
trial [5] are: histopathological or cytologic confirmation, an
Eastern Cooperative Oncology Group (ECOG) performance
status of 0, 1 or 2, a total serum bilirubin level of 1.5 times
the upper limit of normal (ULN) range or less, liver-enzyme
levels of 5 times the ULN range or less, levels of serum urea
and serum creatinine of 1.5 times the ULN range or less and
a calculated glomerular filtration of 45ml/min or higher. The
Institutional Review Boards of both centers approved the
study and the need for informed consent was waived.
Toxicity was scored using the common terminology criteria
for adverse events (CTCAE) version 4.03 [10]. Radiologic
response evaluation was assessed using response evaluation
criteria in solid tumors (RECIST) [11].
Study objectives
The primary objective was to compare OS in patients treated
with gemcitabine plus cisplatin who do versus who do not
fulfill the inclusion criteria of the ABC-02 trial. Secondary
objectives were to investigate differences in progression-free
survival (PFS) and toxicity between the two predefined
groups. We also compared these data with the patients that
were eligible for treatment but opted for best supportive
care instead of chemotherapy (group III).
Statistical analysis
All statistical analyses were performed using SPSS version 22
(IBM corp). Descriptive statistics for categorical variables were
reported as percentages, and continuous variables were
reported as medians and ranges. Categorical variables were
compared using Chi square test and continuous variables
were compared using the independent-samples t-test.
Dose intensity was calculated as the cumulative dose of
gemcitabine per body surface area divided by the time
between the date of the first administration and the end of
the last cycle of chemotherapy. The same calculation was
used to calculate dose intensity of cisplatin. The dose inten-
sity of 100% gemcitabine was defined as 666.7mg/m2/week
and for cisplatin as 16.7mg/m2/week [6].
The OS of BTC patients who received chemotherapy was
calculated from the date of first gemcitabine and cisplatin
administration. Survival of the patients who did not receive
chemotherapy was calculated from the date of initial diagno-
sis to death with censoring for patients alive at the last
moment of follow-up. An additional calculation was per-
formed where OS of BTC patients who received chemother-
apy was calculated from the date of initial diagnosis to be
able to compare this to patients who did not receive
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chemotherapy. The PFS in patients receiving chemotherapy
was calculated from the date of first gemcitabine and cis-
platin administration to the date on which radiological or
clinical progression was determined with censoring for
patients with no progressive disease at the end of follow-up
(1 July 2015). The Kaplan–Meier method was used to esti-
mate OS. Multivariate analysis was performed with Cox
Proportional Hazards Model. Survival status was updated
using the municipal records database on 10 February 2016.
Results
Patients and treatment
In total, 208 patients with unresectable BTC were identified
and formed the study cohort (Figure 1). The majority of our
cohort received gemcitabine and cisplatin treatment (n¼ 138,
66.3%). Of these, 74 (53.6%) patients received chemotherapy
and met the criteria of the ABC-02 trial (group I) and 64
(46.4%) patients received chemotherapy and did not meet
these criteria (group II; see Table 1). Seventy patients were
eligible for chemotherapy, but received best supportive care
without any chemotherapy (group III). Patient’s choice was
the most frequent reason for not receiving chemotherapy.
Table 2 presents the baseline patient characteristics. Most
patients were male (54.3%) and the median age of patients
who received chemotherapy and the patients who received
best supportive care were 63 and 72 years, respectively.
Group I had more patients with gallbladder tumors and
less patients bile duct tumors compared to group II (gallblad-
der: 23.0% vs. 12.5%; bile duct: 64.9% vs. 81.3% p¼ .303). In
group II, significantly more patients had interventions prior
to chemotherapy, most frequently a PTC (6.8% vs. 26.6%
p¼ .002). The majority of patients in group III had bile duct
as primary tumor site (67.6%) and 91.2% of group III patients
underwent a previous therapy.
Overall survival and progression free survival
The median OS of the entire cohort was 8.8
(95%CI¼ 7.5–10.1) months. Patients who received chemother-
apy and met the criteria of the ABC-02 trial had a median
OS, calculated from date of first administration of chemother-
apy, of 9.6 (95%CI¼ 6.7–12.5) months, which was comparable
with 9.5 (95%CI¼ 7.7–11.3) months in patients who received
chemotherapy and did not meet these criteria (p¼ .731;
Figure 2(A)). If OS is calculated from date of initial diagnosis,
all patients treated with gemcitabine plus cisplatin (group I
and II combined) had a median OS of 14.8
(95%CI¼ 11.7–17.8) months compared with patients who
received best supportive care without chemotherapy of 7.6
(95%CI¼ 5.0–10.2) months (p< .001). Median PFS of patients
in group I was 6.0 (95%CI¼ 4.4–7.6) months, compared to
5.1 (95%CI¼ 3.7–6.5) months of patients in group II (p¼ .495;
Figure 2(B)). In a multivariable analysis that included WHO
performance status, body mass index (BMI), extent of disease,
primary tumor site and previous therapies, we did not iden-
tify receiving chemotherapy according to the ABC-02 criteria
or not as an independent prognostic factor for survival
(HR¼ 0.83, 95%CI¼ 0.56–1.24).
ErasmusMC cohort 
N=402 
AMC cohort
N=619
Paents not eligible for palliave 
chemotherapy (e.g. resecon) 
N=392 
Incomplete data (e.g. treated in other 
hospitals, no palliave treatment) 
N=416 
Paents eligible for palliave 
treatment 
N= 624 
Chemotherapy, meet 
the criteria 
= Group I 
N=76 
Chemotherapy, did 
not meet the criteria 
= Group II 
N=62 
No chemotherapy  
= Group III 
N=70 
Figure 1. Flow chart. ErasmusMC, Erasmus Medical Center. AMC, Amsterdam Medical Center. The ErasmusMC cohort consists of only perihilar cholangiocarcinoma
patients and some additional BTC patients from a systematic search in the pharmacy registers. The AMC cohort consists of all unresectable BTC patients between
January 2010 and January 2015. BTC was defined as intra- or extrahepatic cholangiocarcinoma or gallbladder cancer.
Table 1. Did not meet the criteria of the ABC-02 trial based on.
Variable Group II (N¼ 64)
Age >18 years n (%) 0 (0.0)
Histological or cytologic diagnosis n (%) 5 (7.8)
ECOG PS n (%) 1 (1.5)
Serum bilirubin level >1.5 times ULN n (%) 15 (23.4)
Serum liver-enzyme levels >5 times ULN n (%) 55 (85.9)
Serum ureum and creatinine level >1.5 times ULN n (%) 2 (3.1)
eGFR <45ml/min n (%) 2 (3.1)
ECOG PS: Eastern Cooperative Oncology Group performance status; ULN: upper
limit of normal; eGFR: calculated glomerular filtration.
Liver enzyme levels including: alanine-transaminase, aspartate-transaminase,
gamma-glutamyltransferase and alkaline phosphatase.
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Chemotherapy treatment
Table 3 shows the comparison of outcomes of the patients
who received chemotherapy and met the criteria of the ABC-
02 trial versus those who received chemotherapy and did
not meet these criteria. The dose-intensity is comparable
between both groups. The main reason for ceasing chemo-
therapy treatment was disease progression.
Toxicity
Table 4 shows the grade 3 and 4 toxicity of the chemother-
apy treatment in group I and II. Patients in group II more
often had a decrease in platelet count as a result of chemo-
therapy treatment (8.2% vs. 18.8%, p=.079). Other toxicities
were comparable between the two groups.
Discussion
In this study, we found that patients receiving treatment
with gemcitabine and cisplatin who did not meet the inclu-
sion criteria of the ABC-02 trial, have comparable OS, PFS,
toxicity and chemotherapy dose reduction rates compared
with patients who fulfilled the inclusion criteria of the ABC-
02 trial.
Biliary tract cancer (BTC) is an uncommon cancer with a
poor prognosis. The ABC-02 trial demonstrated that a chemo-
therapy combination of gemcitabine plus cisplatin was asso-
ciated with a significant survival advantage without the
Table 2. Patients characteristics.
Variable
Chemotherapy in daily
practice (N¼ 138)
Gem–Cis arm ABC-02
Trial (N¼ 204)
Group I
(N¼ 74)
Group II
(N¼ 64) p-Value
Group III
(N¼ 70)
Age in years
Median 63 63.9 64 63 .504 72
Range 35–79 32.8–81.9 35–77 40–79 – 41–86
Sex- no. (%) .431
Female 61 (44.2) 108 (52.9) 35 (47.3) 26 (40.6) – 34 (48.6)
Male 77 (55.8) 96 (47.1) 39 (52.7) 38 (59.4) – 36 (51.4)
Extent of disease – no. (%) .094
Locally advanced 38 (27.5) 55 (27.0) 16 (21.6) 22 (34.4) – 32 (46.4)
Metastatic 100 (72.5) 149 (73.0) 58 (78.4) 42 (65.6) – 36 (52.2)
Primary tumor site – no. (%) .099
Gallbladder 25 (18.1) 73 (35.8) 17 (23.0) 8 (12.5) – 14 (20.6)
Bile duct 100 (72.5) 122 (59.8) 48 (64.9) 52 (81.3) – 46 (67.6)
Ampulla 7 (5.1) 9 (4.4) 6 (8.1) 1 (1.6) – 6 (8.8)
Unclear 6 (4.3) 0 3 (4.1) 3 (4.7) – 2 (2.9)
ECOG performance-status score – no. (%) .543
0 52 (37.7) 66 (32.4) 30 (40.5) 23 (35.9) – 16 (22.9)
1 72 (52.2) 111 (54.4) 37 (50.0) 35 (54.7) – 20 (28.6)
2 11 (8.0) 27 (13.2) 7 (9.5) 4 (6.3) – 8 (11.4)
3 1 (0.7) 0 0 1 (1.6) – 3 (4.3)
Unknown 2 (1.4) 0 0 1 (1.6) – 23 (32.9)
Previous therapy – no. (%) .073
No 31 (22.5) 50 (24.5) 21 (28.4) 10 (15.6) – 6 (8.8)
Yes 107 (77.5) 154 (75.5) 53 (71.6) 54 (84.4) – 62 (91.2)
Type of previous therapy –no. (%)
Surgery 62 (44.9) 74 (36.2) 35 (47.3) 27 (42.2) .547 31 (45.6)
Biliary stenting 64 (46.4) 93 (45.6) – – – –
PTC-drain – – 5 (6.8) 17 (26.6) .002 15 (22.1)
ERCP with biliary stenting – – 39 (39.2) 35 (54.7) .069 44 (64.7)
Radiotherapy 5 (3.6) 3 (1.5) 2 (2.7) 2 (3.1) .883 3 (4.4)
Other therapy 37 (26.8) 76 (37.3) 9 (12.2) 6 (9.4) .600 5 (7.4)
BMI (kg/m2)
Median – – 24.7 23.4 .286 24.2
Range – – 16.7–38.0 17.2–52.1 – 16.0–38.6
Gem–Cis arm: gemcitabine plus cisplatin tretment arm of the ABC-02 trial; PTC: percutaneous transhepatic cholangiography; ERCP: endoscopic retrograde cholan-
giopancreatography; BMI: body mass index; ECOG: Eastern Cooperative Oncology Group. Bile duct includes intrahepatic, hilar- and extra- hepatic cholangiocarci-
noma. p-Values are calculated for the comparison of group I vs. group II.
 
Number at risk 
Group I 69 25 9 4 
Group II 63 24 7 2 
Group III 65 20 3 3 
Number at risk 
Group I 67 5 2 2 
Group II 58 8 4 2 
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Figure 2. Survival rates: (A) overall survival, (B) progression-free survival.
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addition of substantial toxicity compared to gemcitabine
monotherapy. However, inclusion criteria are strict and most
patients in clinical practice do not fulfill the inclusion criteria
of this ABC-02 trial. To provide more evidence about the effi-
cacy and safety of chemotherapy in the heterogeneous
group of unresectable BTC patients, it is necessary to extend
inclusion criteria [12].
To our best knowledge, this is the largest retrospective
analysis since gemcitabine and cisplatin has become the
standard chemotherapeutic regimen for advanced BTC. One
of the strengths of this study is the large patient population
with BTC derived from two specialized centers, including
detailed data on the diagnosis, treatment, toxicity and tumor
evaluation. All patients received the same standard treatment
according to the ESMO guidelines [6]. Not all of these
patients are treated in the specialized centers, but were
referred back to peripheral hospitals to receive the
chemotherapy.
When comparing our study cohort with the ABC-02 trial
cohort, there are several differences to note. Considering
patients’ characteristics, the primary tumor site in patients
treated in the ABC-02 trial was more often gallbladder and
less often bile duct (gallbladder: 18.1% vs. 35.8%; bile duct:
72.5% vs. 59.8%). The median OS in patients receiving
chemotherapy in our study cohort was 9.5 (95%CI¼ 7.9–11.1)
months, compared with a median OS of 11.7 (95%CI=-
9.5–14.3) months in the ABC-02 trial. Median PFS of patients
treated in daily practice was 5.6 (95%CI¼ 4.5–6.7) months
compared with 8.0 (95%CI¼ 6.6–8.6) months in the ABC-02
trial.
The different survival between the patients in our study
cohort and the ABC-02 trial can be explained by the differen-
ces in the patients’ characteristics such as primary tumor site
and previous therapies. More previous therapies might lead
to a selection bias, because patients might have a positive
effect of these other therapies besides the chemotherapy. In
the ABC-02 trial, more patients had gallbladder cancer in
comparison to our study cohort. As seen in the ABC-02 trial,
there was a higher partial response rate to chemotherapy in
patients with gallbladder cancer compared to patients with
cholangiocarcinoma. In general, patients with gallbladder
cancer have a shorter OS compared to cholangiocarcinoma,
but this might be different in patients who are treated with
gemcitabine and cisplatin [13]. The way OS is calculated, can
also contribute to a difference in OS between our cohort and
the OS in patients in the ABC-02 trial. In the ABC-02 trial, OS
Table 3. Treatment and outcomes.
Variable Group I (N¼ 73) Group II (N¼ 64) p-Value
Cycles per patient .688
Median (range) 6 (1–16) 6 (1–16) –
Dose gemcitabine (mg/m2) .286
Median (range) 17400 (1720–55186) 19200 (1910–51200) –
Dose cisplatin (mg/m2) .544
Median (range) 425 (25–1388) 482 (48–1388) –
Dose reduction – no. (%) .974
No 50 (68.5) 44 (68.8) –
Yes 23 (31.5) 20 (31.3) –
Dose intensity gemcitabine – no. (%) .550
95% 23 (31.9) 25 (39.7) –
85–94% 16 (22.2) 11 (17.5) –
75–84% 10 (13.9) 5 (7.9) –
<75% 23 (31.9) 22 (34.9) –
Dose intensity cisplatin – no. (%) .343
95% 20 (27.8) 26 (41.3) –
85–94% 17 (23.6) 12 (19.0) –
75–84% 8 (11.1) 8 (12.7) –
<75% 27 (37.5) 17 (27.0) –
Reason chemotherapy stopped – no. (%) .729
Toxicity 14 (19.2) 10 (15.6) –
Progressive disease 25 (34.2) 26 (40.6) –
Other reason 16 (21.9) 16 (25.0) –
For one patient in both groups dose intensity could not be calculated.
Table 4. Grade 3 or 4 toxic effects during treatment.
Variable Chemotherapy in daily practice (N¼ 137) Group I (N¼ 73) Group II (N¼ 64) p-Value
Hematologic toxic effects – no. (%)
Decreased white-cell count 16 (11.7) 9 (12.3) 7 (10.9) .153
Decreased platelet count 18 (13.1) 6 (8.2) 12 (18.8) .079
Decreased haemoglobin count 9 (6.6) 6 (8.2) 3 (4.7) .289
Decreased neutrophil count 45 (32.8) 26 (35.6) 19 (29.7) .423
Liver function – no. (%)
Increased alanine aminotransferase level 6 (4.4) 4 (5.5) 2 (3.1) .503
Other abnormal liver function 26 (19.0) 10 (13.7) 16 (25.0) .224
Non-hematologic toxic effects – no. (%)
Infection – 8 (11.0) 6 (9.4) .941
Fatigue/nausea/vomiting – 3 (4.1) 2 (3.1) .867
Renal function – 2 (2.7) 0 .407
Toxicity according to CTCAE 4.0. For one patient in group I, there were no data available on toxicity. p-Values were calculated for the comparison of group I vs.
group II.
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is calculated from date of randomisation in comparison with
date of first administration of chemotherapy in our study
cohort.
In our study cohort, we also observed a higher toxicity
rate than in the ABC-02 trial. Neutropenia and thrombocyto-
penia occurred more frequently in our study. Since this is a
retrospective analysis, not all toxicities were reported system-
atically, which may have led to an underestimation of tox-
icity. The higher toxicity rate in our study, resulting in more
dose reductions, might be a possible explanation for the
lower median survival in patients treated in daily practice.
Moreover, the higher toxicity rate in our study cohort can be
explained by less restrictive inclusion criteria for part of the
patients in comparison to the ABC-02 trial.
The AMC and EMC are highly specialized tertiary institutes
for BTC, which may have caused a selection bias, because
the majority of these referred patients needed drainage and
may possibly have had a poorer baseline situation than
patients who are not referred to the AMC or EMC. This could
explain the difference in median OS and PFS between
patients who received chemotherapy in daily practice and
patients in the ABC-02 trial (OS 9.5 vs. 11.7 months; PFS 5.6
vs. 8.0 months), because patients without drainage problems
are more likely not to be referred to a highly specialized ter-
tiary institute.
In contrast with a recent similar retrospective analysis in
26 metastatic BTC patients [14], we observed a difference in
OS in patients treated with gemcitabine and cisplatin in daily
practice compared with patients in the ABC-02 trial. Almost
half of these patients [14] (49%) received second or third line
chemotherapy, which may explain the higher OS in the other
retrospective analysis (9.5 vs. 10.5 months).
When comparing patients who received chemotherapy in
daily practice and met the criteria of the ABC-02 trial and
patients who did not meet these criteria, we found no differ-
ences in median OS or PFS. Patients in group I had a higher
2.5-year survival rate in comparison with patients in group II
(2.5-year survival: 12.9% vs. 5.1% respectively). This suggests
a treatment advantage of chemotherapy, after careful patient
selection, based on criteria used in the original clinical trials.
Although eligible for chemotherapy treatment, 70 patients
received best supportive care rather than chemotherapy.
These patients were older than patients who did receive
chemotherapy. Although, the ECOG performance status was
missing in 32.9% (n¼ 23) of patients that received best sup-
portive care, the impaired clinical condition of these patients
may explain why they did not receive any chemotherapy but
best supportive care instead.
Several limitations of the current study should be men-
tioned. Since it is a retrospective analysis, not all required
data were systematically reported and therefore not avail-
able. The administration of chemotherapy and toxicities were
not reported unambiguously.
In conclusion, our study shows that patients who did not
meet the inclusion criteria of the ABC-02 trial but receiving
an identical chemotherapy regimen, had comparable OS, PFS,
toxicity and chemotherapy dose reduction rates compared
with patients who did fulfill the ABC-02 trial inclusion criteria.
Patients with unresectable BTC who received gemcitabine
plus cisplatin had a better OS than patients who received
best supportive care in real life practice. Patients with unre-
sectable BTC who do not meet the original inclusion criteria
used in the ABC-02 trial should still be considered for gemci-
tabine plus cisplatin treatment.
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